Real‐world safety and effectiveness of cenobamate in patients with focal onset seizures: Outcomes from an Expanded Access Program

This study investigated early, real‐world outcomes with cenobamate (CNB) in a large series of patients with highly drug‐resistant epilepsy within a Spanish Expanded Access Program (EAP).

[1]  B. Steinhoff,et al.  Failure to use new breakthrough treatments for epilepsy , 2023, Epilepsia.

[2]  N. Delanty,et al.  Adjunctive cenobamate in highly active and ultra‐refractory focal epilepsy: A “real‐world” retrospective study , 2023, Epilepsia.

[3]  C. Bien,et al.  A retrospective non‐interventional study evaluating the pharmacokinetic interactions between cenobamate and clobazam , 2023, Epilepsia.

[4]  F. Villani,et al.  Use of cenobamate for the treatment of focal epilepsy: an Italian expert opinion paper , 2022, Expert review of neurotherapeutics.

[5]  A. Schulze-Bonhage,et al.  Effects of cenobamate on cognitive performance of epilepsy patients , 2022, Seizure.

[6]  C. Kellinghaus,et al.  Successful treatment of adult Dravet syndrome patients with cenobamate , 2022, Epilepsia.

[7]  J. Stern,et al.  Dose Adjustment of Concomitant Antiseizure Medications During Cenobamate Treatment: Expert Opinion Consensus Recommendations , 2022, Neurology and Therapy.

[8]  S. Dupont,et al.  The burden of epilepsy and unmet need in people with focal seizures , 2022, Brain and behavior.

[9]  T. Mayer,et al.  Real-World Experience Treating Pediatric Epilepsy Patients With Cenobamate , 2022, Frontiers in Neurology.

[10]  B. Steinhoff,et al.  Long-term Efficacy and Safety From an Open-Label Extension of Adjunctive Cenobamate in Patients With Uncontrolled Focal Seizures , 2022, Neurology.

[11]  S. Kothare,et al.  Adjunctive use of cenobamate for pediatric refractory focal-onset epilepsy: A single-center retrospective study , 2022, Epilepsy & Behavior.

[12]  A. Williamson,et al.  Effectiveness and safety of adjunctive cenobamate for focal seizures in adults with developmental disability treated in clinical practice , 2022, Epilepsy & behavior reports.

[13]  B. Steinhoff,et al.  Efficacy and safety of adjunctive cenobamate: Post-hoc analysis of study C017 in patients grouped by mechanism of action of concomitant antiseizure medications , 2022, Seizure.

[14]  E. Perucca,et al.  Cenobamate: A Review of its Pharmacological Properties, Clinical Efficacy and Tolerability Profile in the Treatment of Epilepsy. , 2022, CNS & neurological disorders drug targets.

[15]  J. Wheless,et al.  Initial Real-World Experience With Cenobamate in Adolescents and Adults: A Single Center Experience. , 2022, Pediatric neurology.

[16]  Josemir W Sander,et al.  Long‐term individual retention with cenobamate in adults with focal seizures: Pooled data from the clinical development program , 2021, Epilepsia.

[17]  M. Sperling,et al.  Efficacy of cenobamate for uncontrolled focal seizures: Post hoc analysis of a Phase 3, multicenter, open‐label study , 2021, Epilepsia.

[18]  M. Sperling,et al.  Post hoc analysis of a phase 3, multicenter, open‐label study of cenobamate for treatment of uncontrolled focal seizures: Effects of dose adjustments of concomitant antiseizure medications , 2021, Epilepsia.

[19]  J. Serratosa,et al.  Identifying key unmet needs and value drivers in the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through Multi-Criteria Decision Analysis (MCDA) , 2021, Epilepsy & Behavior.

[20]  W. Rosenfeld,et al.  Efficacy of adjunctive cenobamate based on number of concomitant antiseizure medications, seizure frequency, and epilepsy duration at baseline: A post-hoc analysis of a randomized clinical study , 2021, Epilepsy Research.

[21]  G. Jackson,et al.  The costs of epilepsy in Australia , 2020, Neurology.

[22]  Steve S. Chung,et al.  Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures , 2020, Neurology.

[23]  M. Sperling,et al.  Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open‐label safety study , 2020, Epilepsia.

[24]  B. Steinhoff,et al.  Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial , 2019, The Lancet Neurology.

[25]  S. Patten,et al.  The impact of seizures on epilepsy outcomes: A national, community‐based survey , 2017, Epilepsia.

[26]  B. Steinhoff,et al.  Randomized controlled antiepileptic drug trials miss almost all patients with ongoing seizures , 2017, Epilepsy & Behavior.

[27]  D. Jayne,et al.  SUMMARY OF PRODUCT CHARACTERISTICS , 2014 .

[28]  R. Duncan.  Faculty Opinions recommendation of Quantifying the response to antiepileptic drugs: effect of past treatment history. , 2010 .

[29]  J. Cramer,et al.  The evolution of antiepileptic drug development and regulation , 2010, Epileptic disorders : international epilepsy journal with videotape.

[30]  G. Mathern,et al.  Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies , 2009, Epilepsia.

[31]  T. Egberts,et al.  Clinical relevance of patients with epilepsy included in clinical trials , 2008, Epilepsia.

[32]  Y. Schiller,et al.  Quantifying the response to antiepileptic drugs , 2008, Neurology.

[33]  V. Akila,et al.  Information , 2001, The Lancet.